These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
241 related articles for article (PubMed ID: 30875757)
1. Obatoclax, a BH3 Mimetic, Enhances Cisplatin-Induced Apoptosis and Decreases the Clonogenicity of Muscle Invasive Bladder Cancer Cells via Mechanisms That Involve the Inhibition of Pro-Survival Molecules as Well as Cell Cycle Regulators. Steele TM; Talbott GC; Sam A; Tepper CG; Ghosh PM; Vinall RL Int J Mol Sci; 2019 Mar; 20(6):. PubMed ID: 30875757 [TBL] [Abstract][Full Text] [Related]
3. CDK inhibitors upregulate BH3-only proteins to sensitize human myeloma cells to BH3 mimetic therapies. Chen S; Dai Y; Pei XY; Myers J; Wang L; Kramer LB; Garnett M; Schwartz DM; Su F; Simmons GL; Richey JD; Larsen DG; Dent P; Orlowski RZ; Grant S Cancer Res; 2012 Aug; 72(16):4225-37. PubMed ID: 22693249 [TBL] [Abstract][Full Text] [Related]
4. Obatoclax, a Pan-BCL-2 Inhibitor, Targets Cyclin D1 for Degradation to Induce Antiproliferation in Human Colorectal Carcinoma Cells. Or CR; Chang Y; Lin WC; Lee WC; Su HL; Cheung MW; Huang CP; Ho C; Chang CC Int J Mol Sci; 2016 Dec; 18(1):. PubMed ID: 28035994 [TBL] [Abstract][Full Text] [Related]
5. The pan-Bcl-2 blocker obatoclax promotes the expression of Puma, Noxa, and Bim mRNA and induces apoptosis in neoplastic mast cells. Peter B; Cerny-Reiterer S; Hadzijusufovic E; Schuch K; Stefanzl G; Eisenwort G; Gleixner KV; Hoermann G; Mayerhofer M; Kundi M; Baumgartner S; Sperr WR; Pickl WF; Willmann M; Valent P J Leukoc Biol; 2014 Jan; 95(1):95-104. PubMed ID: 24052572 [TBL] [Abstract][Full Text] [Related]
6. Repression of GRIM19 expression potentiates cisplatin chemoresistance in advanced bladder cancer cells via disrupting ubiquitination-mediated Bcl-xL degradation. Ni F; Yan CY; Zhou S; Hui PY; Du YH; Zheng L; Yu J; Hu XJ; Zhang ZG Cancer Chemother Pharmacol; 2018 Oct; 82(4):593-605. PubMed ID: 30032449 [TBL] [Abstract][Full Text] [Related]
8. MLN4924 Synergistically Enhances Cisplatin-induced Cytotoxicity via JNK and Bcl-xL Pathways in Human Urothelial Carcinoma. Ho IL; Kuo KL; Liu SH; Chang HC; Hsieh JT; Wu JT; Chiang CK; Lin WC; Tsai YC; Chou CT; Hsu CH; Pu YS; Shi CS; Huang KH Sci Rep; 2015 Nov; 5():16948. PubMed ID: 26592553 [TBL] [Abstract][Full Text] [Related]
9. Inhibition of MCL-1 by obatoclax sensitizes Sp2/0-Ag14 hybridoma cells to glutamine deprivation-induced apoptosis. Harnett CC; Abusneina A; Clément J; Gauthier ER Cell Biochem Funct; 2015 Jul; 33(5):334-40. PubMed ID: 26178811 [TBL] [Abstract][Full Text] [Related]
10. MiR-34a chemosensitizes bladder cancer cells to cisplatin treatment regardless of p53-Rb pathway status. Vinall RL; Ripoll AZ; Wang S; Pan CX; deVere White RW Int J Cancer; 2012 Jun; 130(11):2526-38. PubMed ID: 21702042 [TBL] [Abstract][Full Text] [Related]
11. Arctigenin anti-tumor activity in bladder cancer T24 cell line through induction of cell-cycle arrest and apoptosis. Yang S; Ma J; Xiao J; Lv X; Li X; Yang H; Liu Y; Feng S; Zhang Y Anat Rec (Hoboken); 2012 Aug; 295(8):1260-6. PubMed ID: 22619087 [TBL] [Abstract][Full Text] [Related]
12. Upregulated expression of BCL2, MCM7, and CCNE1 indicate cisplatin-resistance in the set of two human bladder cancer cell lines: T24 cisplatin sensitive and T24R2 cisplatin resistant bladder cancer cell lines. Kim SH; Ho JN; Jin H; Lee SC; Lee SE; Hong SK; Lee JW; Lee ES; Byun SS Investig Clin Urol; 2016 Jan; 57(1):63-72. PubMed ID: 26966728 [TBL] [Abstract][Full Text] [Related]
13. Inhibition of Pyruvate Kinase M2 Markedly Reduces Chemoresistance of Advanced Bladder Cancer to Cisplatin. Wang X; Zhang F; Wu XR Sci Rep; 2017 Apr; 7():45983. PubMed ID: 28378811 [TBL] [Abstract][Full Text] [Related]
14. Knockdown of Bmi1 inhibits bladder cancer cell growth both in vitro and in vivo by blocking cell cycle at G1 phase and inducing apoptosis. Luo HB; Li B; Yuan WG; Xu CR J Huazhong Univ Sci Technolog Med Sci; 2015 Oct; 35(5):730-735. PubMed ID: 26489630 [TBL] [Abstract][Full Text] [Related]
15. Pan-Bcl-2 inhibitor Obatoclax is a potent late stage autophagy inhibitor in colorectal cancer cells independent of canonical autophagy signaling. Koehler BC; Jassowicz A; Scherr AL; Lorenz S; Radhakrishnan P; Kautz N; Elssner C; Weiss J; Jaeger D; Schneider M; Schulze-Bergkamen H BMC Cancer; 2015 Nov; 15():919. PubMed ID: 26585594 [TBL] [Abstract][Full Text] [Related]
16. A small molecule pan-Bcl-2 family inhibitor, GX15-070, induces apoptosis and enhances cisplatin-induced apoptosis in non-small cell lung cancer cells. Li J; Viallet J; Haura EB Cancer Chemother Pharmacol; 2008 Mar; 61(3):525-34. PubMed ID: 17505826 [TBL] [Abstract][Full Text] [Related]
17. Single-agent obatoclax (GX15-070) potently induces apoptosis and pro-survival autophagy in head and neck squamous cell carcinoma cells. Yazbeck VY; Li C; Grandis JR; Zang Y; Johnson DE Oral Oncol; 2014 Feb; 50(2):120-7. PubMed ID: 24216166 [TBL] [Abstract][Full Text] [Related]
18. Platinum resistant cancer cells conserve sensitivity to BH3 domains and obatoclax induced mitochondrial apoptosis. Crawford N; Chacko AD; Savage KI; McCoy F; Redmond K; Longley DB; Fennell DA Apoptosis; 2011 Mar; 16(3):311-20. PubMed ID: 21107700 [TBL] [Abstract][Full Text] [Related]
19. Apoptosis of bladder cancer by sodium butyrate and cisplatin. Maruyama T; Yamamoto S; Qiu J; Ueda Y; Suzuki T; Nojima M; Shima H J Infect Chemother; 2012 Jun; 18(3):288-95. PubMed ID: 22041988 [TBL] [Abstract][Full Text] [Related]
20. The BH3 Mimetic Obatoclax Accumulates in Lysosomes and Causes Their Alkalinization. Stamelos VA; Fisher N; Bamrah H; Voisey C; Price JC; Farrell WE; Redman CW; Richardson A PLoS One; 2016; 11(3):e0150696. PubMed ID: 26950068 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]